ResMed Posts 1Q EPS of $2.92
RMD sits 40% above its 52-week low of $180.265.
Summary
ResMed reported first-quarter EPS of $2.92 and adjusted EPS of $2.91, with net income of $418.4M on revenue of $1.41B. The company also declared a $0.66 dividend. The release still carries no margin or guidance detail and no year-ago comparison, so the beat/miss picture isn't yet clear. Context matters here: the company just began issuing revenue guidance last quarter and is absorbing $41.9M in Astral recall costs while winding down that ventilator line in fiscal 2027. The $450M accelerated share repurchase with Citibank also trims the share count, which flatters per-share figures. Full release details will determine whether this is a clean beat or a cost-driven number.
At the time of this announcement, RMD was trading at $252.83 on NYSE in the Life Sciences sector, with a market capitalization of approximately $35.6B. The 52-week trading range was $180.27 to $277.67. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.